Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence
Research output: Contribution to journal › Review article
Colleges, School and Institutes
- Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Chicago, Chicago, IL.
- Department of Obstetrics and Gynaecology, University of Toronto, Ontario, Canada and TRIO Fertility, Toronto Ontario, Canada.
- Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Aalborg, Denmark.
- Birmingham Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Bordesley Green East, Birmingham, United Kingdom.
- Tommy's Charity, Laurence Pountney Hill, London, United Kingdom.
- Carver College of Medicine, University of Iowa Health Care, Iowa City, IA.
- Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, United Kingdom.
- University of Warwick
- Imperial College London
- University of Amsterdam
- King's College London
- University of Glasgow
- Monash University
- University of Perugia
- I.M. Sechenov First Moscow State Medical University
- Newcastle upon Tyne Hospitals NHS Foundation Trust
Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone supplementation may reduce the risk of miscarriage in women with recurrent or threatened miscarriage. Cochrane Reviews summarized the evidence and found that the trials were small with substantial methodologic weaknesses. Since then, the effects of first-trimester use of vaginal micronized progesterone have been evaluated in 2 large, high-quality, multicenter placebo-controlled trials, one targeting women with unexplained recurrent miscarriages (the PROMISE [PROgesterone in recurrent MIScarriagE] trial) and the other targeting women with early pregnancy bleeding (the PRISM [PRogesterone In Spontaneous Miscarriage] trial). The PROMISE trial studied 836 women from 45 hospitals in the United Kingdom and the Netherlands and found a 3% greater live birth rate with progesterone but with substantial statistical uncertainty. The PRISM trial studied 4153 women from 48 hospitals in the United Kingdom and found a 3% greater live birth rate with progesterone, but with a P value of .08. A key finding, first observed in the PROMISE trial, and then replicated in the PRISM trial, was that treatment with vaginal micronized progesterone 400 mg twice daily was associated with increasing live birth rates according to the number of previous miscarriages. Prespecified PRISM trial subgroup analysis in women with the dual risk factors of previous miscarriage(s) and current pregnancy bleeding fulfilled all 11 conditions for credible subgroup analysis. For the subgroup of women with a history of 1 or more miscarriage(s) and current pregnancy bleeding, the live birth rate was 75% (689/914) with progesterone vs 70% (619/886) with placebo (rate difference 5%; risk ratio, 1.09, 95% confidence interval, 1.03-1.15; P=.003). The benefit was greater for the subgroup of women with 3 or more previous miscarriages and current pregnancy bleeding; live birth rate was 72% (98/137) with progesterone vs 57% (85/148) with placebo (rate difference 15%; risk ratio, 1.28, 95% confidence interval, 1.08-1.51; P=.004). No short-term safety concerns were identified from the PROMISE and PRISM trials. Therefore, women with a history of miscarriage who present with bleeding in early pregnancy may benefit from the use of vaginal micronized progesterone 400 mg twice daily. Women and their care providers should use the findings for shared decision-making.
|Number of pages||10|
|Journal||American journal of obstetrics and gynecology|
|Early online date||31 Jan 2020|
|Publication status||Published - Aug 2020|
- bleeding, luteal phase deficiency, meta-analysis, recurrent miscarriage, threatened miscarriage, vaginal micronized progesterone